TITLE

In Other News

PUB. DATE
June 2005
SOURCE
Pharmaceutical Representative;Jun2005, Vol. 35 Issue 6, p14
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article presents information related to drugs and drug approval in the U.S. At the request of the Food and Drug Administration (FDA), Pfizer Inc. has suspended U.S. sales and marketing of its COX-2 selective nonsteroidal anti-inflammatory drug (NSAID) Bextra or valdecoxib. The FDA has also asked manufacturers to add a boxed warning to the labeling of all prescription NSAIDs and to revise the labeling of all over-the-counter NSAIDs to point out the increased risks of cardiovascular events and gastrointestinal bleeding associated with these drugs.
ACCESSION #
17482088

 

Related Articles

  • Speak Out. Griffin, Andrew S. // Urology Times;2/1/2005, Vol. 33 Issue 2, p28 

    Presents the views of physicians regarding the withdrawal of rofecoxib by the U.S. Food and Drug Administration from the market and the drug approval process of the Agency. Change in the type of drugs prescribed by physicians; Shortcomings of the Agency in the drug approval process; Risk-benefit...

  • Pennsaid.  // Formulary;Jan2010, Vol. 45 Issue 1, p4 

    The article presents information on a new formulation for the drug Pennsaid, a nonsteroidal anti-inflammatory topical solution for use in the treatment of the signs and symptoms associated with knee osteoarthritis. The drug was approved by the U.S. Food and Drug Administration (FDA) in November...

  • FDA APPROVES NSAID TO ADDRESS DOSE-RELATED SAFETY CONCERNS.  // Medical Economics;11/10/2013, Vol. 90 Issue 21, p17 

    The article reports on the approval of diclofenac (Zorvolex) capsules, a nonsteroidal anti-inflammatory drug (NSAID), for the management of mild-to-moderate acute pain in adults, by the U.S. Food and Drug Administration (FDA). Zorvolex is the only NSAID created using proprietary SoluMatrix Fine...

  • FDA Accepts Roxro's NDA for ROX-888.  // Bioworld Week;2/16/2009, Vol. 17 Issue 7, p2 

    The article reports on the announcement of Roxro Pharma Inc. in California that its application for ROX-888, an intranasal formulation of the nonsteroidal anti-inflammatory drug (NSAID) ketoralac, was approved by the U.S. Food and Drug Administration. It states that ketorolac was the only NSAID...

  • New Methotrexate Injector. R., L. // Arthritis Today;Nov/Dec2014, Vol. 28 Issue 6, p32 

    The article reports on the approval of the U.S. Food and Drug Administration (FDA) of an injectable form of methotrexate known as Rasuvo intended for adults with rheumatoid arthritis (RA) or psoriasis and for children with polyarticular juvenile idiopathic arthritis.

  • FDA yanks Bextra, mandates NSAID warnings. Crespi-Lofton, Judy // Pharmacy Today;May2005, Vol. 11 Issue 5, p10 

    The article reports that reacting to months of criticism about swift approvals and slow responses to postmarketing problems, the U.S. Food and Drug Administration (FDA) took more drastic action than many expected, ordering valdecoxib off the U.S. market and adding boxed warnings to the labeling...

  • RUBBING AWAY PAIN.  // Good Housekeeping;Jun2008, Vol. 246 Issue 6, p39 

    The article reports that the pain reliever Voltaren Gel is the first medicine to be approved by the U.S. Food & Drug Administration for osteoarthritis. It is stated that unlike other pain relievers like ibuprofen and naproxen sodium, only 6% of Voltaren is absorbed into the bloodstream. It is...

  • Another COX-2 recalled.  // Patient Care;May2005, Vol. 39 Issue 5, p10 

    Reports on the request by the U.S. Food and Drug Administration (FDA) that Pfizer, Inc. voluntarily withdraw Bextra (Valdecoxib) from the market on April 7, 2005, after concluding that the drug's overall risk versus benefit profile is unfavorable. Basis of the decision of the FDA; Demand of FDA...

  • Is it bye-bye Bextra in the US, EU and Canada?  // Reactions Weekly;4/16/2005, Issue 1047, p2 

    Reports on the decision of Pfizer Inc. to suspend the sales and marketing of Bextra in the U.S., European Union and Canada. Reasons for the withdrawal of Bextra from the market, according to the U.S. Food and Drug Administration (FDA); Request of FDA for the manufacturers of nonsteroidal...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics